The China Study - Complete References

Appendix C

1. Holick MF. In: M. E. Shils, J. A. Olson, M. Shike and e. al (eds.), Modern nutrition in health and disease, 9th ed., pp. 329–345. Baltimore, MD: Williams and Wilkins, 1999.

2. Barger-Lux MJ, Heaney R, Dowell S, et al. "Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men." Osteoporosis Int. 8 (1998): 222–230.

3. The biological half-life of storage vitamin D is 10–19 days, the time it takes for half of it to disappear.

4. Colston KW, Berger U, and Coombes RC. "Possible role for vitamin D in controlling breast cancer cell proliferation." Lancet 1 (1989): 188–191.

5. Nieves J, Cosman F, Herbert J, et al. "High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis." Neurology 44 (1994): 1687–1692.

6. Al-Qadreh A, Voskaki I, Kassiou C, et al. "Treatment of osteopenia in children with insulin dependent diabetes mellitus: the effect of 1-alpha hydroxyvitamin D3." Eur. J. Pediatr. 155 (1996): 15–17.

7. Cantorna MT, Hayes CE, and DeLuca HF. "1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis." Proc. National Acad. Sci 93 (1996): 7861–7864.

8. Rozen F, Yang X-F, Huynh H, et al. "Antiproliferative action of vitamin D-related compounds and insulin-like growth factor-binding protein 5 accumulation." J. Nat. Cancer Inst. 89 (1997): 652–656.

9. Cosman F, Nieves J, Komar L, et al. "Fracture history and bone loss in patients with MS." Neurology 51 (1998): 1161–1165.

10. Giovannucci E, Rimm E, Wolk A, et al. "Calcium and fructose intake in relation to risk of prostate cancer." Cancer Res. 58 (1998): 442–447.

11. Peehl DM, Krishnan AV, and Feldman D. "Pathways mediating the growth-inhibitory action of vitamin D in prostate cancer." J. Nutr. 133(Suppl) (2003): 2461S–2469S.

12. Zella JB, McCary LC, and DeLuca HF. "Oral administration of 1,25-dihydroxyvitamin D3 completely protects NOD mice from insulin-dependent diabetes mellitus." Arch. Biochem Biophys. 417 (2003): 77–80.

13. Davenport CB. "Multiple sclerosis from the standpoint of geographic distribution and race." Arch. Neurol. Pschiatry 8 (1922): 51–58.

14. Alter M, Yamoor M, and Harshe M. "Multiple sclerosis and nutrition." Arch. Neurol. 31 (1974): 267–272.

15. Van der Mei IA, Ponsonby AL, Blizzard L, et al. "Regional variation in multiple sclerosis prevalence in Australia and its association with ambivalent ultraviolet radiaion." Neuroepidemiology 20 (2001): 168–174.

16. McLeod JG, Hammond SR, and Hallpike JF. "Epidemiology of multiple sclerosis in Australia. With NSW and SA survey results." Med. J. Austr 160 (1994): 117–122.

17. Holick MF. "Vitamin D: a millenium perspective." J. Cell. Biochem. 88 (2003): 296–307.

18. MacLaughlin JA, Gange W, Taylor D, et al. "Cultured psoriatic fibroblasts from involved and uninvolved sites have a partial, but not absolute resistance to the proliferation-inhibtion activity of 1,25-dihydroxyvitamin Ds." Proc. National Acad. Sci 52 (1985): 5409–5412.

19. Goldberg P, Fleming MC, and Picard EH. "Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D." Med. Hypoth. 21 (1986): 193–200.

20. Andjelkovic Z, Vojinovic J, Pejnovic N, et al. "Disease modifying and immunomodulatory effects of high dose 1a(OH)D3 in rheumatoid arthritis patients." Clin. Exp. Rheumatol. 17 (1999): 453–456.

21. Hypponen E, Laara E, Reunanen A, et al. "Intake of vitamin D and risk of Type 1 diabetes: a birth-cohort study." Lancet 358 (2001): 1500–1503.

22. Breslau NA, Brinkley L, Hill KD, et al. "Relationship of animal protein-rich diet to kidney stone formation and calcium metabolism." J. Clin. Endocrinol. Metab. 66 (1988): 140–146.

23. Langman CB. "Calcitriol metabolism during chronic metabolic acidosis." Semin. Nephrol. 9 (1989): 65–71.

24. Chan JM, Giovannucci EL, Andersson S-O, et al. "Dairy products, calcium, phosphorus, vitamin D, and risk of prostate cancer (Sweden)." Cancer Causes and Control 9 (1998): 559–566.

25. Byrne PM, Freaney R, and McKenna MJ. "Vitamin D supplementation in the elderly: review of safety and effectiveness of different regimes." Calcified Tissue Int. 56 (1995): 518–520.

26. Agranoff BW, and Goldberg D. "Diet and the geographical distribution of multiple sclerosis." Lancet 2(7888) (November 2 1974): 1061–1066.

27. Akerblom HK, Vaarala O, Hyoty H, et al. "Environmental factors in the etiology of Type 1 diabetes." Am. J. Med. Genet. (Semin. Med. Genet.) 115 (2002): 18–29.

28. Chan JM, Stampfer MJ, Ma J, et al. "Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer." J Natl Cancer Inst 94 (2002): 1099–1109.

29. Cohen P, Peehl DM, and Rosenfeld RG. "The IGF axis in the prostate." Horm. Metab. res. 26 (1994): 81–84.

30. Doi SQ, Rasaiah S, Tack I, et al. "Low-protein diet suppresses serum insulin-like growth factor-1 and decelerates the progression of growth hormone-induced glomerulosclerosis." Am. J. Nephrol. 21 (2001): 331–339.

31. Heaney RP, McCarron DA, Dawson-Hughes B, et al. "Dietary changes favorably affect bond remodeling in older adults." J. Am. Diet. Assoc. 99 (1999): 1228–1233.

32. Allen NE, Appleby PN, Davey GK, et al. "Hormones and diet: low insulin-like growth factor-I but normal bioavailable androgens in vegan men." Brit. J. Cancer 83 (2000): 95–97__